Manel Kraeim Merabet
Chief Development Officer Skymab Biotherapeutics
Dr. Manel Kraiem Merabet is Chief Development Officer at Skymab, with over 11 years of experience in translational and clinical oncology research. Formerly a Scientific leader at Innate Pharma, she led ADC programs from target selection, lead optimization to IND and is regarded as an ADC expert. She is the patent inventor of several ADCs, including ADCs anti-GPCRs, IPH45, currently under clinical development. Dr. Merabet has served as Chair of multiple sessions, including the Linker Summit in Boston, the ADC Summit in Amsterdam and 4th Annual GPCRs-Targeted Drug Discovery Summit. She holds a PharmD, a PhD in Oncology and Immunology, a European radiopharmacy–radiobiology degree from CEA Saclay, and a Master’s in Organic Chemistry from Saint Jerome University. She collaborates with leading biotech and pharma partners and has been recognized as an invited expert speaker at major ADC and oncology conferences, including the World ADC Summit.
Seminars
- Revisiting GPCRs as viable oncology targets through the lens of mature ADC technologies, combining deep biological insight with innovative antibody design
- ADC optimization tailored to GPCR biology by balancing antigen density, expression heterogeneity, and internalization for maximal efficacy and selectivity
- Implementing a holistic design framework to match antibody properties, linker– payload chemistry, and target features to create next-generation, GPCR-directed ADC therapeutics
